|
|
|
|
| LEADER |
00000cz a2200000n 4500 |
| 001 |
100151434 |
| 003 |
DE-627 |
| 005 |
20231225211605.0 |
| 008 |
120418n||aznnnabbn | ana |c |
| 024 |
7 |
|
|a http://d-nb.info/gnd/5314-4
|2 uri
|
| 035 |
|
|
|a (DE-588)5314-4
|
| 035 |
|
|
|a (DE-627)100151434
|
| 035 |
|
|
|a (DE-576)190170824
|
| 035 |
|
|
|z (DE-588b)5314-4
|9 v:zg
|
| 043 |
|
|
|c XD-US
|
| 079 |
|
|
|a g
|b b
|c v
|q f
|v kiz
|
| 110 |
2 |
|
|a American Society for Pharmacology and Experimental Therapeutics
|
| 410 |
2 |
|
|a Society for Pharmacology and Experimental Therapeutics
|g USA
|
| 410 |
2 |
|
|a ASPET
|4 abku
|w r
|i Abkuerzung
|e Abkuerzung
|
| 410 |
2 |
|
|a American Association for Pharmacology and Experimental Therapeutics
|
| 410 |
2 |
|
|a ASPET
|g American Society for Pharmacology and Experimental Therapeutics
|
| 410 |
2 |
|
|a American Society for Pharmacology and Experimental therapeutics
|
| 548 |
|
|
|a 1908-
|4 datb
|w r
|i Zeitraum
|
| 551 |
|
|
|0 (DE-627)106076612
|0 (DE-576)209209682
|0 (DE-588)4078704-7
|a USA
|4 geow
|w r
|i Wirkungsraum
|
| 667 |
|
|
|a zu 4101Parallelform
|5 CH-ZuETHN
|
| BEA |
|
|
|a Kalliope Verbundkatalog
|u https://kalliope-verbund.info/gnd/5314-4
|0 lr
|
| ORI |
|
|
|a SA-MARC-krimdokc001.raw
|
| SUB |
|
|
|a KRI
|b 1
|
GND (5314-4)